Patents Examined by Joan Ellis
  • Patent number: 4985361
    Abstract: Human pancreatic elastase can now be obtained from a genetically engineered source.
    Type: Grant
    Filed: October 13, 1987
    Date of Patent: January 15, 1991
    Assignee: Sankyo Company, Limited
    Inventors: Yo Takiguchi, Tokio Tani, Ichiro Kawashima, Jun Ohsumi, Hidehiko Furukawa, Toshinori Ohmine
  • Patent number: 4978621
    Abstract: DNA sequences are described which encode Plasmodium falciparum merozoite antigenic surface proteins and protein fragments. Corresponding recombinant plasmids and transformed bacterial strains are described. The proteins and fragments have utility for immunological and diagnostic purposes.
    Type: Grant
    Filed: June 1, 1989
    Date of Patent: December 18, 1990
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Feroza Ardeshir, Janette E. Flint, Robert T. Reese
  • Patent number: 4973551
    Abstract: An expression vector which can be used to express fusion proteins which are useful as immunogens. The vector is characterized as a 3.35 kilobase pair vector having origins for replication and selectivity markers for bacteria. The plasmid has an E. coli promotor segment, a CheY fusion protein sequence and a unique restriction site at the 3' end of the CheY segment for preparing a DNA segment which codes for a foreign protein to be expressed.
    Type: Grant
    Filed: January 15, 1988
    Date of Patent: November 27, 1990
    Assignee: Merck & Co., Inc.
    Inventor: Jon H. Condra
  • Patent number: 4973478
    Abstract: Interferon .beta..sub.2 has been identified as the major factor responsible for stimulating hepatocytes to produce anti-inflammatory agents. A method for its use in so stimulating hepatocytes is described herein.
    Type: Grant
    Filed: July 20, 1987
    Date of Patent: November 27, 1990
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Jack Gauldie, Richards, Carl, Peter M. Lansdorp
  • Patent number: 4968614
    Abstract: Human pancreatic elastase I can be obtained by genetic engineering.
    Type: Grant
    Filed: April 21, 1987
    Date of Patent: November 6, 1990
    Assignee: Sankyo Company Limited
    Inventors: Yo Takiguchi, Tokio Tani, Hidehiko Furukawa, Ohmine, Toshinori, Kawashima, Ichiro
  • Patent number: 4966846
    Abstract: Neutral protease genes from Vibrio proteolyticus or Bacillus can be cloned and expressed in gram-negative microorganisms, such as E. coli or Serratia. The functional neutral protease enzyme is expressed.
    Type: Grant
    Filed: November 19, 1987
    Date of Patent: October 30, 1990
    Assignee: W. R. Grace & Co.-Conn.
    Inventors: Alan H. Deutch, Victor A. David
  • Patent number: 4965195
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: October 7, 1988
    Date of Patent: October 23, 1990
    Assignee: Immunex Corp.
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
  • Patent number: 4960700
    Abstract: DNA isolates coding for enkephalinase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of enkephalinase for use in therapeutic or diagnostic compositions. Enkephalinase assays are facilitated by novel enkephalinase substrates.
    Type: Grant
    Filed: January 12, 1987
    Date of Patent: October 2, 1990
    Assignee: Genentech, Inc.
    Inventors: Bernard Malfroy-Camine, Peter R. Schofield
  • Patent number: 4952499
    Abstract: The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4.sup.+ helper/inducer T cells relative to activated CD4.sup.+ cells. The invention also relates to the proteins encoded by such genes, termed rpt-1 proteins, which regulate gene expression directed by the promoter region of the interleukin-2 receptor (IL-2r) alpha chain gene or by the promoter region of the long terminal repeat of human lymphotropic retroviruses such as the human immunodeficiency virus type 1 (HIV-1) human T cell leukemia virus (HTLV)-I, and HTLV-II. In particular, rpt-1 proteins down-regulate gene expression controlled by the promoter of the IL-2r alpha chain gene or by the promoter of the long terminal repeat of HIV-1. The proteins and nucleic acids of the invention have value in diagnosis and therapy of immune disorders such as AIDS.
    Type: Grant
    Filed: February 11, 1988
    Date of Patent: August 28, 1990
    Assignee: Dana-Farber Cancer Institute
    Inventors: Harvey I. Cantor, Roberto Patarca
  • Patent number: 4948731
    Abstract: A recombinant plasmid which may be used for propagation of cloned cDNAs and also for the in vitro synthesis of RNA which is an exact copy of the natural sequence, wherein the transcript is devoid of vector-derived sequence. The novel vector was generated de novo by genetic engineering procedures using a synthetic double strand oligodeoxyribonucleotide fragment and a larger DNA fragment derived from plasmid pSP64. The vector, plasmid pHST-O, carried by Escherichia coli HB101, deposited with the ATCC on Dec.
    Type: Grant
    Filed: August 5, 1986
    Date of Patent: August 14, 1990
    Assignee: Massachusetts Institute of Technology
    Inventors: Lee Gehrke, Robert T. Fraley, Stephen G. Rogers
  • Patent number: 4935366
    Abstract: A method is described of obtaining cellulase deficient strains which have great ability to degrade lignin at the same time. The method comprises crossing a homokaryotic cellulase deficient mutant of a white-rot fungus having a full sexual cycle with a homokaryotic strain of the same fungus, this strain having great lignin degrading ability. Strains are subsequently selected that have great lignin degrading ability in combination with cellulase deficiency. A suitable white-rot fungis is Phanerochaete chrysosporium. The crossings are suitably performed for a plurality of generations. The strain of white-rot fungus obtained is used for delignifying lignocellulosic material.
    Type: Grant
    Filed: May 16, 1986
    Date of Patent: June 19, 1990
    Assignee: Svenska Traforskningsinstitutet
    Inventors: Karl-Erik Eriksson, Susanna C. Johnsrud
  • Patent number: 4925794
    Abstract: New hybrid plasmids which are useful as vectors in recombinant DNA in which Acremonium chrysogenum or Saccharomyces cerevisiae is used as a host, and microorganisms bearing the hybrid plasmids, are disclosed. The disclosure herein is based on the cloning of autonomous replication sequences (ARS) of A. chrysogenum ATCC 11550 and introduction of the ARS into a shuttle vector of E. coli and Saccharomyces cerevisiae and construction of new types of plasmids based on the ARS.
    Type: Grant
    Filed: December 11, 1985
    Date of Patent: May 15, 1990
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Takao Isogai, Masaru Yoshida
  • Patent number: 4914030
    Abstract: The carB gene is a novel carbomycin resistance-conferring gene isolated from Streptomyces thermotolerans and used to construct a number of cloning vectors for use in Streptomyces and related organisms. One such coloning vector, plasmid pOJ159, can be obtained in S. griseofuscus C581 under the accession number NRRL 18090. S. lividans and S. griseofuscus are the preferred hosts when the carB gene is used to select carbomycin-resistant Streptomyces transformants.
    Type: Grant
    Filed: August 28, 1986
    Date of Patent: April 3, 1990
    Assignee: Eli Lilly and Company
    Inventors: Brigitte E. Schoner, Janet K. Epp
  • Patent number: 4904591
    Abstract: The carA gene is a novel carbomycin resistance-conferring gene isolated from Streptomyces thermotolerans and used to construct a number of cloning vectors for use in Streptomyces and related organisms. One such cloning vector, plasmid pOJ158, can be obtained in S. griseofuscus C581 under the accession number NRRL 18089. S. lividans and S. griseofuscus are the preferred hosts when the carA gene is used to select carbomycin-resistant Streptomyces transformants.
    Type: Grant
    Filed: August 28, 1986
    Date of Patent: February 27, 1990
    Assignee: Eli Lilly and Company
    Inventors: Janet K. Epp, Brigitte E. Schoner
  • Patent number: 4894333
    Abstract: Cloning and expression of DNA segments encoding bovine IL-.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: January 16, 1990
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Charles R. Maliszewski, Michael A. Schoenborn
  • Patent number: 4889809
    Abstract: The tlrC gene is a novel tylosin resistance-conferring gene isolated from Streptomyces fradiae and used to construct a number of cloning vectors for use in Streptomyces. One such cloning vector, plasmid pSKC10, can be obtained in S. fradiae JS87 under the accession number NRRL 18072. S. fradiae JS87 is the preferred host when the tlrC gene is used to select tylosin-resistant Streptomyces transformants.
    Type: Grant
    Filed: July 25, 1986
    Date of Patent: December 26, 1989
    Assignee: Eli Lilly and Company
    Inventors: Virginia A. Birmingham, Karen L. Cox, Eugene T. Seno
  • Patent number: 4882280
    Abstract: Different from conventional uricase products, the uricase of the present invention has outstandingly high thermal stability and is active in a wide range of pH from 5 to 10 for the oxidative decomposition of uric acid undertaken in clinical analysis. The uricase of the invention is produced microbiologically by a thermophilic microorganism belonging to the genus of Bacillus and especially named as Bacillus sp. TB-90 which is a novel species distinguishable from any of the microorganisms belonging to the genus of Bacillus.
    Type: Grant
    Filed: May 22, 1986
    Date of Patent: November 21, 1989
    Assignee: Sapporo Breweries Limited
    Inventors: Masachika Takashio, Takahide Chikano, Minoru Kamimura
  • Patent number: 4879241
    Abstract: The tlrB gene is a novel tylosin resistance-conferring gene isolated from Streptomyces fradiae and used to construct a number of cloning vectors for use in Streptomyces and related organisms. One such cloning vector, plasmid pSVB9, can be obtained in S. lividans under the accession number NRRL 18073. S. lividans is the preferred host when the tlrB gene is used to select tylosin-resistant Streptomyces transformants.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: November 7, 1989
    Assignee: Eli Lilly and Company
    Inventors: Virginia A. Birmingham, Eugene T. Seno
  • Patent number: 4876201
    Abstract: A method is provided for effecting the reduction of PCB contamination in organic waste by utilizing a particular strain of a biologically pure culture of Alcaligenes eutrophus under aerobic conditions.
    Type: Grant
    Filed: February 27, 1989
    Date of Patent: October 24, 1989
    Assignee: General Electric Company
    Inventors: Donna L. Bedard, Michael J. Brennan, Jr.
  • Patent number: 4863864
    Abstract: The present invention relates to the Rhizopus derived glucoamylase gene, a novel recombinant vector comprising said gene, and a microorganism transformed by said vector, as well as a process for reproducing Rhizopus glucoamylase by cultivating the transformed microorganism, especially yeast, in a liquid medium.
    Type: Grant
    Filed: December 13, 1985
    Date of Patent: September 5, 1989
    Assignee: Suntory Limited
    Inventors: Toshihiko Ashikari, Norihisa Nakamura, Yoshikazu Tanaka, Yuji Shibano, Hajime Yoshizumi